Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page
- Check5 days agoChange DetectedThe record describes a phase I/II trial of CIMAvax with nivolumab or pembrolizumab for advanced lung or head and neck cancer, including treatment plans, eligibility criteria, locations, and outcome measures. It is listed as active but not recruiting.SummaryDifference75%

- Check12 days agoChange DetectedThe 403 error message and its Home link are no longer displayed; the study-record area appears empty.SummaryDifference0.5%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” was added, and the site revision label advanced from v3.7.1 to v3.7.2. The study-record area still displays a 403 Forbidden error.SummaryDifference1%

- Check40 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now shows a 403 Forbidden error, blocking access to the study record. Previous study-related terms and content appear removed or hidden due to the access restriction.SummaryDifference22%

- Check60 days agoChange DetectedRevision: v3.7.0 has been added, replacing the previous Revision: v3.6.6. The page now reflects the newer revision version.SummaryDifference0.0%

Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.